Skip Navigation LinksHome > January 2010 - Volume 110 - Issue 1 > FDA RAISES SAFETY ISSUES CONCERNING PROPOXYPHENE
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000366058.52347.3f
Drug Watch

FDA RAISES SAFETY ISSUES CONCERNING PROPOXYPHENE

Aschenbrenner, Diane S. MS, APRN, BC

Collapse Box

Abstract

* The FDA now requires a black box warning on the labeling of all drugs containing propoxyphene stating that overdose with the mild opioid analgesic can be fatal.

* The warning also indicates that taking propoxyphene together with strong CYP3A4 inhibitors may enhance propoxyphene plasma levels.

* A medication guide has been developed to alert patients to the hazards of propoxyphene overdosing and other adverse effects of the drug.

© 2010 Lippincott Williams & Wilkins. All rights reserved.

Login